Circulating biomarker [Neurosurgery Wiki]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.
====== Circulating biomarker ======

[[Liquid biopsy]] approaches for detection of circulating [[biomarker]]s of [[cancer]] have been utilized in [[oncology]] in many clinical settings from early detection to disease monitoring. Recent approaches have focused on circulating tumor cells, circulating tumor DNA, and circulating RNAs in a variety of biofluids. However, very little progress has been made in implementing such approaches for detection of brain tumors, despite the tremendous clinical need for earlier and less invasive diagnosis, as well as more accurate assessment of disease status. In a review, Mathios and Phallen highlight the recent methodological improvements in the field of liquid biopsy technologies specifically for glioblastoma. Although many retrospective and few prospective studies have been conducted to assess the utility of circulating biomarkers for detection of brain tumors, none have yet moved forward to clinical implementation
((Mathios D, Phallen J. Circulating Biomarkers in Glioblastoma: Ready for Prime Time? Cancer J. 2021 Sep-Oct 01;27(5):404-409. doi: 10.1097/PPO.0000000000000541. PMID: 34570455.))

It is of great importance to seek further subclassifications in [[glioblastoma multiforme]], [[biomarker]]s, and new treatment modalities to make a significant change in [[survival]] for individuals
((Fekete B, Werlenius K, Örndal C, Rydenhag B. Prognostic factors for
glioblastoma patients - a clinical population-based study. Acta Neurol Scand.
2016 Jun;133(6):434-41. doi: 10.1111/ane.12481. Epub 2015 Sep 11. PubMed PMID:
26358197.
)).